GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

March 12, 2016

To be eligible for the study, potential volunteers must have started antiretroviral therapy within 18 months of a negative HIV antibody test and must remain on stable antiretroviral therapy for six months prior to receiving their first dose of the vaccines.  Multiple potential candidates, identified through the AIDS Research Consortium of Atlanta and the Alabama Vaccine Research Clinic, are currently in the six-month antiretroviral therapy period and the vaccination segment of the clinical trial will soon be initiated.

The GeoVax vaccines are currently being tested in HIV-uninfected persons in a Phase 2 clinical trial by the HIV Vaccine Trials Network (HVTN).  The HVTN trials are funded by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health.  The therapeutic trial is the first GeoVax trial designed to test these vaccines as a treatment for HIV-infected persons.  

SOURCE GeoVax Labs, Inc.